LGT Group Foundation Has $5.80 Million Position in Henry Schein, Inc. $HSIC

LGT Group Foundation lowered its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 49.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 88,336 shares of the company’s stock after selling 86,498 shares during the quarter. LGT Group Foundation owned about 0.08% of Henry Schein worth $5,795,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HSIC. Artisan Partners Limited Partnership raised its position in shares of Henry Schein by 5.7% in the third quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock valued at $453,509,000 after purchasing an additional 370,837 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Henry Schein by 6.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,596,168 shares of the company’s stock worth $172,304,000 after buying an additional 159,087 shares during the period. Ameriprise Financial Inc. grew its stake in Henry Schein by 3,275.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after buying an additional 2,199,695 shares during the last quarter. Schroder Investment Management Group grew its stake in Henry Schein by 149.3% in the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock valued at $114,243,000 after buying an additional 936,471 shares during the last quarter. Finally, Snyder Capital Management L P raised its holdings in Henry Schein by 18.6% in the 3rd quarter. Snyder Capital Management L P now owns 1,334,364 shares of the company’s stock worth $88,562,000 after acquiring an additional 209,123 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on HSIC. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research report on Monday, December 29th. Robert W. Baird set a $100.00 price objective on Henry Schein and gave the stock an “outperform” rating in a research note on Monday, February 23rd. Wells Fargo & Company boosted their price objective on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Leerink Partners restated a “market perform” rating on shares of Henry Schein in a research note on Monday. Finally, JPMorgan Chase & Co. raised their target price on Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $85.58.

Henry Schein Price Performance

Shares of Henry Schein stock opened at $78.10 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.76. The company has a market cap of $8.96 billion, a PE ratio of 23.88, a price-to-earnings-growth ratio of 2.30 and a beta of 0.87. The firm has a fifty day moving average price of $78.23 and a two-hundred day moving average price of $72.70. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $89.29.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.04. The company had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The business’s revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Insider Buying and Selling

In related news, Director Philip A. Laskawy sold 2,844 shares of Henry Schein stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $80.36, for a total transaction of $228,543.84. Following the sale, the director directly owned 21,961 shares of the company’s stock, valued at $1,764,785.96. This trade represents a 11.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stanley M. Bergman sold 43,812 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $81.31, for a total value of $3,562,353.72. Following the transaction, the chief executive officer owned 383,803 shares in the company, valued at $31,207,021.93. This represents a 10.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 101,712 shares of company stock valued at $8,251,789 over the last three months. 1.14% of the stock is owned by corporate insiders.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.